Topic

Ohio

A collection of 479 issues

If Evkeeza Isn't Approved by Aetna CVS Health in Ohio: Formulary Alternatives & Exception Paths

Answer Box: If Aetna CVS Health denies Evkeeza (evinacumab-dgnb) for homozygous familial hypercholesterolemia (HoFH) in Ohio, you have two main paths: try formulary alternatives like Repatha (evolocumab) or Juxtapid (lomitapide), or appeal for a formulary exception. Aetna prefers PCSK9 inhibitors as first-line specialty therapy, requiring documented failure of maximally tolerated
5 min read

How to Get Myozyme (Alglucosidase Alfa) Covered by Cigna in Ohio: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Myozyme (Alglucosidase Alfa) Covered by Cigna in Ohio Cigna requires prior authorization for Myozyme (alglucosidase alfa) in Ohio, typically approved within 5-7 business days when complete documentation is submitted. Essential requirements include confirmed Pompe disease diagnosis (enzyme/genetic testing), metabolic specialist prescriber, and dosing ≤20 mg/kg
5 min read

Work With Your Doctor to Get Koselugo (Selumetinib) Approved by UnitedHealthcare in Ohio: Complete Provider Collaboration Guide

Answer Box: Getting Koselugo Covered by UnitedHealthcare in Ohio Koselugo (selumetinib) requires prior authorization from UnitedHealthcare for pediatric patients ≥2 years with NF1 plexiform neurofibromas. Your doctor must submit clinical documentation proving NF1 diagnosis, inoperable symptomatic tumors, and baseline safety evaluations. If denied, you have 180 days for internal appeals,
6 min read

How to Get Haegarda (C1-Esterase Inhibitor) Covered by Humana in Ohio: Complete PA Guide and Appeal Scripts

Answer Box: Getting Haegarda Covered by Humana in Ohio Fastest path to approval: Humana requires prior authorization for Haegarda (C1-esterase inhibitor, SC) with confirmed hereditary angioedema diagnosis (ICD-10 D84.1), documented C4/C1-INH lab abnormalities, and specialist prescriber. Submit PA through Humana's provider portal with complete clinical documentation.
6 min read